Siluet tablets 2 + 0.03mg, # 21
Russian Pharmacy name:
Силует таблетки 2+0,03мг, №21
contraception;
treatment of mild to moderate acne (acne) when local treatment is ineffective in women who need contraception.
Inside, 1 table / day, every day, at about the same time, if necessary, squeeze it with a small amount of liquid, in the order indicated on the blister pack, for 21 days. Taking the tablets from the next package begins 7 days after taking the last tablet from the previous package, during which withdrawal bleeding usually occurs. It usually starts 2-3 days after taking the last pill and may not end when you start taking the pills from the next pack.
Switching from progesterone-only pills can be done any day.
If hormonal contraception has not been used before (for a month)
Taking SiluetЃ should be started on the 1st day of the menstrual cycle (i.e., on the 1st day of menstruation).
In case of switching from a PDA
It is preferable to start taking SiluetЃ the next day after the usual interruption in taking or the next day after the last dose of the last tablet from the current oral contraceptive package.
Injection form, implants
The transition from the use of implants is carried out on the day of removal of the implant; when switching from an injection form - the day after the last injection.
After an abortion in the first trimester of pregnancy
You can start taking it immediately; in this case, there is no need to use additional contraceptives.
After childbirth or abortion in the second trimester
It is recommended to start taking the drug on the 21-28th day after childbirth or abortion in the second trimester of pregnancy. If the drug is started later, the woman should be warned about the need to use additional barrier methods (condom) within the first 7 days. However, if sexual intercourse has already occurred, pregnancy must be excluded or until the 1st menstrual period is started before taking the PDA.
Taking missed pills
If the delay in taking the drug is less than 12 hours, contraceptive protection is not reduced. The woman should take the drug as soon as possible, and the next pill should be taken at the usual time. If the delay in taking the pill is more than 12 hours, contraceptive protection may be reduced. In this case, you can be guided by the following two basic rules:
- taking the drug should never be interrupted for more than 7 days;
- It takes 7 days of continuous pill intake to achieve adequate suppression of hypothalamic-pituitary-ovarian regulation.
Accordingly, the following tips can be given if the delay in taking the tablets is more than 12 hours.
1st week A woman should take the last missed tablet as soon as possible, even if it means taking 2 tablets. at the same time. The next pill is taken at the usual time. Additionally, a barrier method of contraception (such as a condom) must be used for the next 7 days. If you have had intercourse within a week before skipping the pill, you must take into account the likelihood of pregnancy. The more pills are missed and the closer this gap is to the 7-day pill break, the higher the risk of pregnancy.
2nd week A woman should take the last missed tablet as soon as possible, even if it means taking 2 tablets. at the same time. The next pill is taken at the usual time. In the event that the woman correctly took the pills within 7 days before the admission, there is no need for additional contraception. However, if she missed more than 1 tablet, she should use additional methods of contraception (condom) for 7 days.
3rd week The risk of reduced reliability is inevitable due to the upcoming 7-day interruption in admission. However, by adjusting the pill schedule, the weakening of contraceptive protection can be prevented. If one of the 2 proposed methods is followed, there is no need to use additional methods of contraception if the woman correctly took the pills within 7 days before the admission. Otherwise, she must follow 1 of these 2 methods, and also use additional methods of contraception for the next 7 days.
1. A woman should take the last missed tablet as soon as possible, even if it means taking 2 tablets. at the same time. The next pill is taken at the usual time. Taking pills from the next blister pack should be started immediately after taking the previous one, i.e. there should be no usual break between doses. Most likely, the woman will not have withdrawal bleeding until the end of the 2nd pack, but she may have spotting spotting or breakthrough uterine bleeding on the days of taking the pills.
2. It is possible to stop taking the tablets from the current blister pack. Then there should be a 7-day break from taking the pills, including the days of missed pills, and then you need to start taking the pills from a new package. If a woman missed taking a pill and then in the 1st normal interval between doses of the drug she does not have withdrawal bleeding, pregnancy must be excluded.
If the woman vomits within 4 hours after taking the pill
Absorption may not be complete and additional contraceptive measures must be taken. In these cases, you should take a new (replacement) pill as soon as possible. If possible, a new tablet should be taken within 12 hours after the usual time of taking. If more than 12 hours have passed, you should follow the recommendations for skipping pills in the section Taking the missed pills.
If the woman does not want to change her normal pill regimen, she must use an additional pill from another blister pack.
How to delay withdrawal bleeding
In order to delay the onset of menstrual bleeding, a woman should continue taking SiluetЃ from a new package immediately after taking all the tablets from the previous one, without interruption. While taking the drug from the 2nd package, a woman may experience spotting or breakthrough uterine bleeding. You should resume taking SiluetЃ from a new pack after the usual 7-day break.
In order to postpone the day of the onset of menstrual bleeding to another day of the week, a woman can be advised to shorten the next break in taking the pill for as many days as she wants. The shorter the interval, the higher the risk that there will be no withdrawal bleeding and in the future, while taking the next pack, spotting and breakthrough bleeding will appear (as well as in the case when she would like to delay the onset of menstrual bleeding).
Film-coated tablets | 1 tab. |
active substances: | |
ethinyl estradiol | 0.03 mg |
dienogest | 2 mg |
excipients: lactose monohydrate - 47.66 mg; corn starch - 10.46 mg; hypromellose 2910 - 0.65 mg; talc - 1.6 mg; polacrilin potassium - 1.3 mg; magnesium stearate - 1.3 mg | |
film shell: Opadry II white 85F18422 (polyvinyl alcohol - 1.2 mg, titanium dioxide - 0.750 mg, macrogol 3350 - 0.606 mg, talc - 0.444 mg) - 3 mg |
Combined oral contraceptives (COCs) should not be used if any of the conditions / diseases listed below are present in the woman. At the first appearance of any of these conditions while taking a PDA, the drug should be stopped immediately:
hypersensitivity to SiluetЃ or any of its components;
current or history of arterial and venous thromboembolic diseases (eg deep vein thrombosis, pulmonary embolism);
thrombosis (arterial and venous) and thromboembolism at present or in history, incl. thrombosis, deep vein thrombophlebitis; pulmonary embolism, myocardial infarction, ischemic or hemorrhagic cerebrovascular disorders;
conditions preceding thrombosis (including transient ischemic attacks, angina pectoris, complicated lesions of the valvular apparatus of the heart, atrial fibrillation, subacute bacterial endocarditis, extended surgery with prolonged immobilization, extensive trauma);
pancreatitis with severe hypertriglyceridemia at present or in history;
porphyria;
jaundice, congenital hyperbilirubinemia (Gilbert, Dubin-Johnson and Rotor syndrome);
sickle cell anemia;
multiple or severe risk factors for venous or arterial thrombosis; a history of risk factors for arterial thrombosis:
- diabetes mellitus with vascular complications (angiopathy, retinopathy);
- uncontrolled arterial hypertension (AH);
- severe dyslipoproteinemia.
congenital or acquired predisposition to arterial thrombosis, for example, resistance to activated protein C, antithrombin III deficiency, protein C, S deficiency, hyperhomocysteinemia and the presence of antibodies to phospholipids (antibodies to cardiolipin, lupus anticoagulant);
smoking over the age of 35;
severe forms of liver disease (including history) before normalization of liver function tests;
liver tumors (benign or malignant), incl. history;
hormone-dependent malignant diseases of the genitals or mammary glands, incl. history, or suspicion of them;
vaginal bleeding of unknown origin;
migraine with local neurological symptoms, incl. history;
epilepsy;
lactase deficiency, lactose intolerance, glucose-galactose malabsorption;
pregnancy;
lactation period.
With caution: the presence of risk factors (varicose veins, heart disease, overweight, blood clotting disorders) requires a more thorough study before starting to take a PDA; smoking under the age of 35 (if a woman cannot quit smoking, another method of contraception should be used, especially if there are other risk factors); the potential risk and expected benefit of the use of oral contraceptives in each individual case should be carefully weighed in the presence of the following diseases, conditions or risk factors: dyslipoproteinemia, diabetes mellitus without vascular complications, controlled arterial hypertension, fibrocystic breast disease, uterine myoma, endometriosis, multiple sclerosis, history of severe depression, renal impairment, contact lens intolerance,Crohn's disease, ulcerative colitis, phlebitis of superficial veins, thromboembolism, acute cerebrovascular accident, myocardial infarction at a young age, chronic heart failure, breast cancer in 1st degree relatives; visual impairment (risk of retinal thrombosis), tetany, hypercalcemia, hypokalemia, bronchial asthma, hereditary angioedema, liver disease, idiopathic jaundice during a previous pregnancy, herpes during pregnancy.bronchial asthma, hereditary angioedema, liver disease, idiopathic jaundice during a previous pregnancy, herpes during pregnancy.bronchial asthma, hereditary angioedema, liver disease, idiopathic jaundice during a previous pregnancy, herpes during pregnancy.
'